In This Article:
As global markets show signs of optimism with easing inflation and strong bank earnings propelling stocks higher, investors are increasingly looking for opportunities beyond the traditional large-cap stocks. Penny stocks, often representing smaller or newer companies, continue to capture attention due to their potential for significant growth. While the term may seem outdated, these investments remain relevant as they can offer value and opportunity when backed by robust financial health.
Top 10 Penny Stocks
Name | Share Price | Market Cap | Financial Health Rating |
DXN Holdings Bhd (KLSE:DXN) | MYR0.50 | MYR2.49B | ★★★★★★ |
Datasonic Group Berhad (KLSE:DSONIC) | MYR0.405 | MYR1.13B | ★★★★★★ |
Bosideng International Holdings (SEHK:3998) | HK$3.69 | HK$42.48B | ★★★★★★ |
Lever Style (SEHK:1346) | HK$0.99 | HK$628.44M | ★★★★★★ |
Begbies Traynor Group (AIM:BEG) | £0.946 | £150.76M | ★★★★★★ |
Hil Industries Berhad (KLSE:HIL) | MYR0.90 | MYR298.75M | ★★★★★★ |
MGB Berhad (KLSE:MGB) | MYR0.72 | MYR425.99M | ★★★★★★ |
ME Group International (LSE:MEGP) | £2.06 | £776.24M | ★★★★★★ |
Stelrad Group (LSE:SRAD) | £1.405 | £178.93M | ★★★★★☆ |
Embark Early Education (ASX:EVO) | A$0.775 | A$142.2M | ★★★★☆☆ |
Click here to see the full list of 5,711 stocks from our Penny Stocks screener.
We'll examine a selection from our screener results.
Uniphar
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Uniphar plc is a diversified healthcare services company operating in the Republic of Ireland, the United Kingdom, The Netherlands, and internationally with a market cap of €556.95 million.
Operations: The company's revenue is derived from three main segments: Pharma (€657.34 million), Medtech (€252.93 million), and Supply Chain & Retail (€1.77 billion).
Market Cap: €556.95M
Uniphar, with a market cap of €556.95 million, operates across Pharma, Medtech, and Supply Chain & Retail segments. Despite its high net debt to equity ratio of 41.1%, its debt is well covered by operating cash flow (54.2%), and interest payments are adequately managed (3.4x EBIT coverage). The company has experienced earnings growth over the past five years at 17.2% annually but saw slower growth last year at 1.4%. Uniphar's recent expansion into cell and gene therapy programs highlights potential in the European pharmaceutical market despite challenges from higher US sales figures for new medicines launched between 2016-2021.
-
Navigate through the intricacies of Uniphar with our comprehensive balance sheet health report here.
-
Review our growth performance report to gain insights into Uniphar's future.
Greenland Hong Kong Holdings
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Greenland Hong Kong Holdings Limited is an investment holding company involved in property development, property and hotel investment, and property management in China, with a market cap of HK$803.06 million.